Literature DB >> 30238432

Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.

Malachi J McKenna1,2, Julie Martin-Grace3, Rachel Crowley3,4, Patrick J Twomey4,5, Mark T Kilbane4,5.   

Abstract

Congenital hypophosphataemia (CH) is a collection of disorders that cause defective bone mineralisation manifesting with rickets in childhood and osteomalacia in adulthood. Bone turnover markers (BTMs) are surrogate measures of metabolic bone disease severity. We explored the utility of BTMs in 27 adults with CH: 23 had X-linked hypophosphataemia (XLH), of whom 2 were hypoparathyroid post-total parathyroidectomy (PTx); 2 had autosomal dominant hypophosphataemic rickets (ADHR), and 2 had none of the known mutations. We measured the renal tubular maximum reabsorption rate of phosphate (TmP/GFR), C-terminal fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), ionised calcium, 1,25-dihydroxyvitamin D [1,25(OH)2D], and a panel of BTMs: serum bone-specific alkaline phosphatase (bone ALP), osteocalcin (Oc), total procollagen type I amino-terminal propeptide (PINP), and carboxy-terminal telopeptide of type I collagen (CTX); and urine amino-terminal telopeptides of type I collagen (uNTX). After excluding 2 patients with XLH and PTx, the frequency of abnormal elevation in BTMs was: bone ALP (96%); CTX (72%); PINP (52%); uNTX (48%); Oc (28%). The strongest association with bone ALP was TmP/GFR. Those patients receiving phosphate supplements and alfacalcidol had significant elevation in CTX. The 2 patients with XLH and PTx had normalisation of TmP/GFR and near normalisation of BTMs post-operatively, despite marked elevation in both C-terminal and intact FGF23. In conclusion, BTMs in our CH patients indicated that most have abnormalities consistent with osteomalacia and many have mild secondary hyperparathyroidism; and the normalisation of TmP/GFR after total PTx in 2 cases of XLH remains unexplained, but possible causes are speculated.

Entities:  

Keywords:  FGF23; Hypophosphataemia; Rickets; Secondary hyperparathyroidism

Mesh:

Substances:

Year:  2018        PMID: 30238432     DOI: 10.1007/s00774-018-0957-5

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  25 in total

1.  Burosumab Therapy in Children with X-Linked Hypophosphatemia.

Authors:  Thomas O Carpenter; Michael P Whyte; Erik A Imel; Annemieke M Boot; Wolfgang Högler; Agnès Linglart; Raja Padidela; William Van't Hoff; Meng Mao; Chao-Yin Chen; Alison Skrinar; Emil Kakkis; Javier San Martin; Anthony A Portale
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

Review 2.  Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation.

Authors:  R B Payne
Journal:  Ann Clin Biochem       Date:  1998-03       Impact factor: 2.057

3.  Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study.

Authors:  Vikram Vinod Shanbhogue; Stinus Hansen; Niklas Rye Jørgensen; Signe Sparre Beck-Nielsen
Journal:  Calcif Tissue Int       Date:  2017-11-15       Impact factor: 4.333

4.  [Key points in nursing of patients with bedsores].

Authors:  H Kawada; F Maeda
Journal:  Kango Kyoshitsu       Date:  1973-06

5.  Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate.

Authors:  O L Bijvoet
Journal:  Clin Sci       Date:  1969-08       Impact factor: 6.124

6.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

7.  Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia.

Authors:  Michael Collins
Journal:  J Bone Miner Res       Date:  2018-07-19       Impact factor: 6.741

Review 8.  A clinician's guide to X-linked hypophosphatemia.

Authors:  Thomas O Carpenter; Erik A Imel; Ingrid A Holm; Suzanne M Jan de Beur; Karl L Insogna
Journal:  J Bone Miner Res       Date:  2011-05-02       Impact factor: 6.741

9.  Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.

Authors:  Xiaoping Zhang; Erik A Imel; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Thomas O Carpenter; Munro Peacock
Journal:  J Clin Pharmacol       Date:  2015-08-11       Impact factor: 3.126

10.  Therapeutic management of hypophosphatemic rickets from infancy to adulthood.

Authors:  Agnès Linglart; Martin Biosse-Duplan; Karine Briot; Catherine Chaussain; Laure Esterle; Séverine Guillaume-Czitrom; Peter Kamenicky; Jerome Nevoux; Dominique Prié; Anya Rothenbuhler; Philippe Wicart; Pol Harvengt
Journal:  Endocr Connect       Date:  2014-03-14       Impact factor: 3.335

View more
  2 in total

Review 1.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

2.  High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series.

Authors:  Mark T Kilbane; Rachel Crowley; Eric Heffernan; Clare D'Arcy; Gary O'Toole; Patrick J Twomey; Malachi J McKenna
Journal:  Bone Rep       Date:  2021-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.